Cargando…
Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
BACKGROUND: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiecta...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869785/ https://www.ncbi.nlm.nih.gov/pubmed/36698687 http://dx.doi.org/10.2147/COPD.S394101 |
_version_ | 1784876839537213440 |
---|---|
author | Kwok, Wang Chun Leung, Sze Him Isaac Tam, Terence Chi Chun Ho, James Chung Man Lam, David Chi-Leung Ip, Mary Sau Man Ho, Pak Leung |
author_facet | Kwok, Wang Chun Leung, Sze Him Isaac Tam, Terence Chi Chun Ho, James Chung Man Lam, David Chi-Leung Ip, Mary Sau Man Ho, Pak Leung |
author_sort | Kwok, Wang Chun |
collection | PubMed |
description | BACKGROUND: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. METHODS: This was a retrospective case control study on the efficacy of BNT162b2 (mRNA vaccine) and CoronaVac (inactivated whole virus vaccine) against COVID-19 in patients with chronic respiratory diseases. A total of 327 patients were included, with 109 patients infected with COVID-19 matched with 218 patients without COVID-19. The co-primary outcomes were vaccine effectiveness against symptomatic COVID-19, COVID-19-related hospitalization and COVID-19-related respiratory failure. Vaccine effectiveness was calculated using the formula (1-adjusted odds ratio) x 100. RESULTS: Patients who received at least 2 doses of CoronaVac had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination, with adjusted odds ratio (OR) of 0.189 (95% CI = 0.050–0.714, p = 0.014) and 0.128 (95% CI = 0.026–0.638, p = 0.012) respectively. Patients who received at least 2 doses of BNT162b2 had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination with adjusted OR of 0.207 (95% CI = 0.043–0.962, p = 0.050) and 0.093 (95% CI = 0.011–0.827, p = 0.033) respectively. There was no statistically significant difference in the risks of being hospitalized for COVID-19 and developing respiratory failure between patients who received at least 2 doses of CoronaVac or BNT162b2. CONCLUSION: BNT162b2 and CoronaVac vaccines are effective in preventing hospitalization for COVID-19 and respiratory failure complicating COVID-19 among patients with chronic respiratory diseases. Patients with chronic respiratory diseases should be encouraged to have COVID-19 vaccination. |
format | Online Article Text |
id | pubmed-9869785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-98697852023-01-24 Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases Kwok, Wang Chun Leung, Sze Him Isaac Tam, Terence Chi Chun Ho, James Chung Man Lam, David Chi-Leung Ip, Mary Sau Man Ho, Pak Leung Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: While different COVID-19 vaccines have been developed, there has been lack of data on the efficacy comparison between mRNA and inactivated whole virus vaccine among patients with chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. METHODS: This was a retrospective case control study on the efficacy of BNT162b2 (mRNA vaccine) and CoronaVac (inactivated whole virus vaccine) against COVID-19 in patients with chronic respiratory diseases. A total of 327 patients were included, with 109 patients infected with COVID-19 matched with 218 patients without COVID-19. The co-primary outcomes were vaccine effectiveness against symptomatic COVID-19, COVID-19-related hospitalization and COVID-19-related respiratory failure. Vaccine effectiveness was calculated using the formula (1-adjusted odds ratio) x 100. RESULTS: Patients who received at least 2 doses of CoronaVac had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination, with adjusted odds ratio (OR) of 0.189 (95% CI = 0.050–0.714, p = 0.014) and 0.128 (95% CI = 0.026–0.638, p = 0.012) respectively. Patients who received at least 2 doses of BNT162b2 had lower risk of being hospitalized for COVID-19 and developing respiratory failure than those who did not have vaccination with adjusted OR of 0.207 (95% CI = 0.043–0.962, p = 0.050) and 0.093 (95% CI = 0.011–0.827, p = 0.033) respectively. There was no statistically significant difference in the risks of being hospitalized for COVID-19 and developing respiratory failure between patients who received at least 2 doses of CoronaVac or BNT162b2. CONCLUSION: BNT162b2 and CoronaVac vaccines are effective in preventing hospitalization for COVID-19 and respiratory failure complicating COVID-19 among patients with chronic respiratory diseases. Patients with chronic respiratory diseases should be encouraged to have COVID-19 vaccination. Dove 2023-01-19 /pmc/articles/PMC9869785/ /pubmed/36698687 http://dx.doi.org/10.2147/COPD.S394101 Text en © 2023 Kwok et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kwok, Wang Chun Leung, Sze Him Isaac Tam, Terence Chi Chun Ho, James Chung Man Lam, David Chi-Leung Ip, Mary Sau Man Ho, Pak Leung Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
title | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
title_full | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
title_fullStr | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
title_full_unstemmed | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
title_short | Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases |
title_sort | efficacy of mrna and inactivated whole virus vaccines against covid-19 in patients with chronic respiratory diseases |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869785/ https://www.ncbi.nlm.nih.gov/pubmed/36698687 http://dx.doi.org/10.2147/COPD.S394101 |
work_keys_str_mv | AT kwokwangchun efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT leungszehimisaac efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT tamterencechichun efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT hojameschungman efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT lamdavidchileung efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT ipmarysauman efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases AT hopakleung efficacyofmrnaandinactivatedwholevirusvaccinesagainstcovid19inpatientswithchronicrespiratorydiseases |